Close Menu

Children's Hospital Los Angeles

Whether they're analyzing checkpoint inhibitors, CAR T cells, or combination regimens, pediatric cancer researchers must carefully consider which targets and drugs to trial.

At the NCI's Childhood Cancer Data Initiative Symposium, speakers emphasized measures such as data harmonization and the need for longitudinal data collection.

Though some experts prefer the comprehensive nature of whole-genome sequencing, others find whole-exome sequencing or targeted exome panels to be more useful.